U.S. Senate reauthorizes FDA to collect fees from drugmakers

Government And Institutions Reuters

FILE - This Oct. 14, 2015 file photo shows the Food and Drug Administration campus in Silver Spring, Md. On Thursday, July 6, 2017, Endo International PLC, the maker of painkiller Opana ER, said it will pull the extended-release opioid drug off the ... market, a month after being urged to do so by U.S. regulators because of abuse. (AP Photo/Andrew Harnik, File) (Copyright 2016 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistribu)

The U.S. Senate on Thursday passed a bill allowing the Food and Drug Administration to continue collecting fees from drug companies to review new product applications.

Continue Reading Below

The FDA Reauthorization Act renews an existing law that expires on Sept. 30 and which provides the majority of FDA funds used to review pharmaceuticals and determine whether they are safe and effective. The Senate passed the bill by a vote of 94-1.

It was passed last month in the House of Representatives.

Separately, the Senate passed a so-called right-to-try bill designed to allow terminally ill patients access to unapproved medications and to provide immunity for physicians willing to administer the treatments. The House has not yet passed that bill. 

(Reporting by Toni Clarke in Washington; Editing by Paul Simao)

What do you think?

Click the button below to comment on this article.